LCA
Landcadia Holdings IV, Inc.
Set alert
10.54 0.00 0.00%
10.54 Day range 10.56
52-week range unavailable
- Open
- 10.55
- Prev close
- 10.54
- Mkt cap
- 142.91M
- Vol
- 48.14K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.54
- High
- 10.56
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.23
- Inst. own
- 81.93%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.50
- 200-d avg
- 10.36
- 1y target
- 0.00
Key statistics
- Market cap
- 142.91M
- Enterprise value
- 145.02M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -0.03
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -614.10K
- Total cash
- 162.03K
- Total debt
- 2.27M
- Return on equity
- 0.00%
- Shares outstanding
- 13.56M
- Short % of float
- 0.01%
- 50-day average
- 10.50
- 200-day average
- 10.36
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
LCA Revenue — quarterly 0
LCA Net income — quarterly 218.29K
LCA EPS — quarterly 0.02
About Landcadia Holdings IV, Inc.
Landcadia Holdings IV, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the dining, hospitality, entertainment, and gaming industries. The company was formerly known as JFG Holding I LLC. Landcadia Holdings IV, Inc. was incorporated in 2020 and is based in Houston, Texas.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
News
- Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
- Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
- Vontier Surpasses 2030 Emissions Target Five Years Early, Sets New 65% Reduction Goal
- Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
- Opus Genetics: Asymmetric Upside With LCA5 And BEST1
- Beyond Meat® Releases 2024 Corporate Responsibility Report and LCA Study that Estimates Environmental Benefits of Beyond Burger® IV, Submits to CDP for First Time
- Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
- Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
- Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
- Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
Your note
Sign in to keep a note on LCA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JEFFERIES FINANCIAL GROUP INC. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 1, 2023 | 0 |
| TJF L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 1, 2023 | 6,250,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mangrove Partners | 33.15% | 450,000 | 4.56M | Jun 29, 2023 |
| UBS OConnor LLC | 3.73% | 50,644 | 513.53K | Jun 29, 2023 |
| Moore Capital Management, LP | 3.68% | 50,000 | 507.00K | Jun 29, 2023 |
| Geode Capital Management, LLC | 3.20% | 43,419 | 440.27K | Jun 29, 2023 |
| Robinson Capital Management, LLC | 2.95% | 40,000 | 405.60K | Jun 29, 2023 |
| Toroso Investments, LLC | 2.95% | 40,000 | 405.60K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 3.20% | 43,419 | 438.97K | May 30, 2023 |
| Tidal ETF Tr-Robinson Alternative Yield Pre-Merger SPAC ETF | 2.95% | 40,000 | 408.80K | Jul 30, 2023 |